Crown Point company begins research partnership with military orgs
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
Purdue University-affiliated OYE Therapeutics Inc. is teaming up with two military medicine research organizations to evaluate the Crown Point company’s intravenous caffeine drug.
OYE Therapeutics is collaborating with the Uniformed Services University of the Health Sciences, a health sciences academy that is akin to a West Point for federal health professionals, and the Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., a nonprofit dedicated to advancing military medicine. Both organizations are based in Bethesda, Maryland.
The research will evaluate the safety and efficacy of OYE Therapeutics’s intravenous caffeine drug, which aims to bring patients out of general anesthesia sooner and accelerate postoperative recovery, according to a news release from Purdue.
Clinical trials will examine how the drug can improve the survivability of wounded soldiers, enhance the safety of combat and medical teams, and optimize recovery, transport and evacuation processes from military care settings, the news release said.
“We are honored to be recognized as a worthy research partner for the military, as they approached us about leveraging our work to benefit injured soldiers,” OYE Therapeutics CEO and founder Brett Dines said. “This is a testament to the hard work and dedication of our entire team, as well as the transformative potential of our technology. We are committed to our mission of providing clinicians with tools to save lives, especially those lives that willingly put themselves in harm’s way to protect others.”
Civilian use cases indicate that the intravenous caffeine drug can reduce mortality rates, lower health care costs and improve surgical workflow efficiency across hospitals, the release said.
OYE Therapeutics operates from the Purdue Technology Center in the Purdue Research Park of Northwest Indiana.